Reviews/Vitamin B12/Maternal vitamin B12 aids neurodevelopment
Neurocognition · VITB12-NEURO-03 · v2
Several randomised trials in this corpus test whether giving mothers vitamin B12 helps their babies' early development, and the results pull in different directions. The largest and most rigorous trial, in 800 women in Nepal, found a worse rather than better outcome on infant motor performance [14], and the main Indian trial found no difference across any developmental measure at nine months [1]. The positive signals that do appear are narrow: one language subdomain at 30 months in that same Indian trial [6], and small cognition and language gains in a very small pre-conceptional trial [8]. The one trial reporting a broad mental-development benefit compared a higher B12 dose against a lower one rather than against no supplement [15][16], so it cannot show that supplementing versus not supplementing helps. Because no single, broad benefit repeats across independent trials, the panel treated the general claim as unsupported by this corpus while stopping short of ruling it out.
The corpus contains four effectively independent human trials, since [1] and [6] are one Indian trial and [15] and [16] are one MATCOBIND trial. The Indian trial found no significant differences in any BSID-III subscale at nine months between B12 (n = 78) and placebo (n = 100) infants [1], with only expressive language higher at 30 months (β = 0.14, P = 0.03) [6]. The Nepal trial in 800 women found a negative effect of B12 on infant motor performance, measured by TIMP in 712 infants at 8 to 12 weeks [14]. The pre-conceptional PRIYA trial reported better cognition (p = 0.044) and language (p = 0.020) in the B12-alone group (n = 21) versus placebo (n = 27) [8]. MATCOBIND reported higher mental developmental quotient in the 250 µg group (103.7) than the 50 µg group (101.7), p = 0.008 [16][15]. The contested point: The division is whether the scattered positive findings amount to a general improvement in neurodevelopment or are subdomain-specific artefacts. The largest, most rigorous trial is null-to-negative [14][1], while the positives are either one isolated subdomain [6], a small fragile trial [8], or a dose comparison with no placebo arm [15][16].
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin B12, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The largest, most rigorous trial (Nepal, 800 women) reported a NEGATIVE effect on infant motor performance [14], and its cognitive outcome was null — this directly contradicts the directional claim of improvement.
MATCOBIND [15]/[16] compares 250 µg vs 50 µg methylcobalamin, with no placebo arm; a dose-response between two B12 doses cannot establish that supplementation versus no supplementation improves neurodevelopment.
Where it remains uncertain. The only broad developmental benefit comes from a 250 µg versus 50 µg dose contrast with no placebo arm [15][16], and the remaining positives are a single language subdomain [6] and a small pre-conceptional trial [8].
Aleatory
PRIYA's supporting estimate rests on n = 21 versus n = 27 [8], so chance variation dominates the result.
Epistemic
MATCOBIND's mental-DQ gain is a 250 µg versus 50 µg contrast [15][16]; whether supplementation versus none improves development is not tested.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Placebo-controlled RCT null at 9 months — counts against a general improvement effect.
“There were no significant differences in any of the subscales of BSID-III between infants born to mothers who received B12 supplementation (n = 78) vs. placebo (n = 100).”
Panel auditInternal validity: high · scope of inference: Cognitive development at 9 months in infants of South Indian women supplemented with 50 µg B12 from early pregnancy to 6 weeks post-partum.Key limitations: small evaluated subset vs randomized N · 9-month outcome only · low 50 µg dose · single population
Same trial at 30 months — one subdomain positive, others not; partial support.
“Children of mothers who received oral vitamin B12 supplementation had significantly higher scores on expressive language compared to children of mothers who received placebo (β = 0.14, P = 0.03).”
Panel auditInternal validity: medium · scope of inference: Expressive language at 30 months in offspring of supplemented South Indian mothers; single positive domain among several tested.Key limitations: single-domain effect · multiple comparisons · small effect size · authors call for confirmation
Small pre-conceptional RCT signal supporting the claim; fragile sample sizes.
“Neurodevelopmental outcomes in the B12 alone group (n = 21) were better than the placebo (n = 27) in cognition (p = 0.044) and language (p = 0.020) domains (adjusted for maternal baseline B12 levels).”
Panel auditInternal validity: low · scope of inference: Neurodevelopment at 2 years in offspring of adolescents supplemented pre-conceptionally with 2 µg/day B12 in rural India.Key limitations: very small analysed subgroups · B12+MMN arm null · pre-conceptional not just pregnancy dosing · borderline p-values
Largest trial shows harm on motor performance — directly contradicts improvement.
“we found a negative effect of maternal vitamin B-12 supplementation during pregnancy on motor performance in their young infants.”
Panel auditInternal validity: high · scope of inference: Early motor performance (TIMP) at 8-12 weeks in infants of supplemented Nepalese women; effect more pronounced where mothers had adequate baseline B12.Key limitations: secondary/subgroup analyses · single motor outcome at early age · one population
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus does not carry a robust general improvement effect — the strongest trial is null-to-negative and positive signals are subdomain-specific, small, or dose comparisons — but replicated subdomain signals keep it short of refuted.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Placebo-controlled trial of a supplementing dose. The only broad benefit is a two-dose contrast with no placebo [15][16], so a true supplementation-versus-none effect is untested. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An adequately powered RCT randomising a supplementing B12 dose against placebo with a pre-specified global neurodevelopment primary outcome.
Open question: Does maternal B12 supplementation versus placebo improve a global measure of infant neurodevelopment? Why it is still open: The broad-benefit trial has no placebo arm [15][16] and the placebo-controlled trials are null-to-negative [1][14].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19